Phase II Trial of Cisplatin and a-Interferon in Advanced Malignant Melanoma

Purpose: To evaluate the antitumor activity of combi-nation cisplatin (CDDP) and a-interferon (a-IFN) in ad-vanced, measurable metastatic melanoma. Patients and Methods: Adult patients with metastatic melanoma were required to have bidimensionally mea-surable lesions and a Karnofsky performance status 2-60%. Serum creatinine s 1.5 mg/dL, creatinine clearance> 60 mL/min, adequate organ and bone marrow func-tion, and radiologic proof of the absence of brain me-tastases were required. CDDP 40 mg/m 2 intravenously (IV) on day 1 and day 8, and a-IFN 3 million units/m2 subcutaneously on days I to 5 and 8 to 12 were adminis-tered every 3 to 4 weeks. Results: Forty-two patients were entered onto this phase II trial and were assessable for response and T HE TREATMENT OF disseminated melanom